Literature DB >> 2448794

Expression of soluble, enzymatically active, human immunodeficiency virus reverse transcriptase in Escherichia coli and analysis of mutants.

A Hizi1, C McGill, S H Hughes.   

Abstract

We have constructed a plasmid that, when introduced into Escherichia coli, induces the synthesis of large quantities of a protein with an apparent molecular mass of 66 kDa that differs from human immunodeficiency virus (HIV) RNA-dependent DNA polymerase (deoxynucleoside-triphosphate:DNA deoxynucleotidyltransferase or reverse transcriptase, EC 2.7.7.49) only in that it has two additional amino-terminal amino acids. This protein is soluble in E. coli extracts, is active in reverse transcriptase assays, and shows inhibition profiles with dideoxy-TTP and dideoxy-GTP that are indistinguishable from the viral enzyme. The deletion of 23 amino-terminal or carboxyl-terminal amino acids or the insertion of 5 amino acids at position 143 substantially decreases the polymerizing activity of the HIV reverse transcriptase made in E. coli. The properties of a 51-kDa reverse transcriptase-related protein made in E. coli suggests that the p51 found in the virion probably does not have substantial polymerizing activity. The full-length HIV reverse transcriptase and the various mutant proteins produced in E. coli should be quite useful for structural and biochemical analyses as well as for the production of antibodies.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2448794      PMCID: PMC279738          DOI: 10.1073/pnas.85.4.1218

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  21 in total

1.  In search of specific inhibitors of retrovirus replication.

Authors:  E De Clercq; J Balzarini
Journal:  Antiviral Res       Date:  1985       Impact factor: 5.970

Review 2.  Inhibitors of retroviral DNA polymerase: their implication in the treatment of AIDS.

Authors:  P Chandra; A Vogel; T Gerber
Journal:  Cancer Res       Date:  1985-09       Impact factor: 12.701

3.  Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV.

Authors:  F di Marzo Veronese; T D Copeland; A L DeVico; R Rahman; S Oroszlan; R C Gallo; M G Sarngadharan
Journal:  Science       Date:  1986-03-14       Impact factor: 47.728

Review 4.  Strategies for antiviral therapy in AIDS.

Authors:  H Mitsuya; S Broder
Journal:  Nature       Date:  1987 Feb 26-Mar 4       Impact factor: 49.962

5.  Expression of reverse transcriptase activity of human T-lymphotropic virus type III (HTLV-III/LAV) in Escherichia coli.

Authors:  N Tanese; J Sodroski; W A Haseltine; S P Goff
Journal:  J Virol       Date:  1986-09       Impact factor: 5.103

6.  RNA-dependent DNA polymerase of avian sarcoma virus B77. I. Isolation and partial characterization of the alpha, beta2, and alphabeta forms of the enzyme.

Authors:  A Hizi; W K Joklik
Journal:  J Biol Chem       Date:  1977-04-10       Impact factor: 5.157

7.  Adaptor plasmids simplify the insertion of foreign DNA into helper-independent retroviral vectors.

Authors:  S H Hughes; J J Greenhouse; C J Petropoulos; P Sutrave
Journal:  J Virol       Date:  1987-10       Impact factor: 5.103

8.  Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides.

Authors:  H Mitsuya; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

9.  Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.

Authors:  P A Furman; J A Fyfe; M H St Clair; K Weinhold; J L Rideout; G A Freeman; S N Lehrman; D P Bolognesi; S Broder; H Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

10.  Human immunodeficiency virus reverse transcriptase. General properties and its interactions with nucleoside triphosphate analogs.

Authors:  Y C Cheng; G E Dutschman; K F Bastow; M G Sarngadharan; R Y Ting
Journal:  J Biol Chem       Date:  1987-02-15       Impact factor: 5.157

View more
  83 in total

1.  Inhibition of the integrases of human immunodeficiency viruses type 1 and type 2 by reverse transcriptases.

Authors:  Iris Oz; Orna Avidan; Amnon Hizi
Journal:  Biochem J       Date:  2002-02-01       Impact factor: 3.857

2.  The ribonuclease H activity of the reverse transcriptases of human immunodeficiency viruses type 1 and type 2 is modulated by residue 294 of the small subunit.

Authors:  Z Sevilya; S Loya; N Adir; A Hizi
Journal:  Nucleic Acids Res       Date:  2003-03-01       Impact factor: 16.971

3.  Mutations in the RNase H domain of HIV-1 reverse transcriptase affect the initiation of DNA synthesis and the specificity of RNase H cleavage in vivo.

Authors:  John G Julias; Mary Jane McWilliams; Stefan G Sarafianos; Edward Arnold; Stephen H Hughes
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-01       Impact factor: 11.205

4.  A redefinition of the Asp-Asp domain of reverse transcriptases.

Authors:  A M Velasco; L Medrano; A Lazcano; J Oró
Journal:  J Mol Evol       Date:  1992-12       Impact factor: 2.395

5.  Inhibition of HIV-1 reverse transcriptase by RNA aptamers in Escherichia coli.

Authors:  David G Nickens; James T Patterson; Donald H Burke
Journal:  RNA       Date:  2003-09       Impact factor: 4.942

6.  Defects in Moloney murine leukemia virus replication caused by a reverse transcriptase mutation modeled on the structure of Escherichia coli RNase H.

Authors:  A Telesnitsky; S W Blain; S P Goff
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

7.  Cassette mutagenesis of the reverse transcriptase of human immunodeficiency virus type 1.

Authors:  P L Boyer; A L Ferris; S H Hughes
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

8.  Characterization of the double stranded RNA dependent RNase activity associated with recombinant reverse transcriptases.

Authors:  H Ben-Artzi; E Zeelon; S F Le-Grice; M Gorecki; A Panet
Journal:  Nucleic Acids Res       Date:  1992-10-11       Impact factor: 16.971

9.  Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitors.

Authors:  A Hizi; R Tal; M Shaharabany; M J Currens; M R Boyd; S H Hughes; J B McMahon
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

10.  Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase.

Authors:  P L Boyer; M J Currens; J B McMahon; M R Boyd; S H Hughes
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.